- Details
- Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...
|
- Details
- Zach Klaassen speaks with Mark Markowski about the advancements in AI, particularly the ArteraAI Prostate Test, and its implications for prostate cancer treatment. Dr. Markowski explains how ArteraAI has evolved from predicting treatment responses in localized prostate cancer to potentially guiding treatment decisions in metastatic hormone-sensitive prostate cancer. The CHAARTED study, a pivotal t...
|
- Details
- Zach Klaassen and Benjamin Maughan discuss new insights into the real-world application of apalutamide in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Maughan highlights the significance of achieving deep PSA responses as a key prognostic marker for patient outcomes. The OASIS project, utilizing data from diverse medical settings across the U.S., demonstrates that patients wh...
|
- Details
- Alicia Morgans speaks with Dan Petrylak about his phase 1 study on a new androgen receptor (AR) degrader, ARV-766. This study explores the potential of AR degraders to effectively target and dismantle androgen receptors in prostate cancer cells, particularly those resistant to conventional therapies. Dr. Petrylak highlights the journey of ARV-766, a second-generation PROTAC drug designed to degrad...
|
- Details
- Alicia Morgans sits down with Christos Kyriakopoulos to discuss the findings from the CHAARTED 2 trial. This study builds on the success of the original CHAARTED trial, focusing on combining standard therapies with second-line chemotherapy to improve outcomes for patients with metastatic castration-resistant prostate cancer. Initiated in 2018 and completed amid the challenges of the COVID-19 pande...
|
- Details
- Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) based on the Alliance trial. The phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone. Despite no difference in overall survival between the treatment arms, Dr. Halabi's team develop...
|
- Details
- Michael Morris shares insights into his presentation on a novel hK2-targeting antibody radioconjugate, JNJ-6420, which uses an actinium radioisotope. Dr. Morris explains that hK2, akin to PSA, binds to prostate cancer cell membranes, making it an ideal target for this radioligand therapy. Unlike existing beta emitters, this alpha-emitting treatment delivers intense, localized radiation, promising...
|
- Details
- PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups. Here we re...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the use of radiopharmaceuticals in prostate cancer, particularly for frail patients. Professor Emmett focuses on dosing radioligand therapy in special situations and managing toxicity, particularly marrow and kidney toxicity. She highlights the need for individualized dosing strategies, noting that current protocols might not adequately treat high-vol...
|
- Details
- Alicia Morgans speaks with Joaquin Mateo about his presentation on PARP inhibitors. Dr. Mateo discusses the role of PARP inhibitors in treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA1 or BRCA2 mutations, noting the poor prognosis associated with these mutations but highlighting the effectiveness of PARP inhibitors like olaparib and rucaparib. He explains the differences...
|
